Montclair-Based FluoroPharma Medical Appoints New CEO

Montclair, NJ – Montclair-based FluoroPharma Medical, a diagnostic imaging product development company, has appointed Thomas Tulip as its new CEO.

According to a company news release, Tulip joined FluoroPharma as President in October of 2015 and assumed responsibility for the company’s day-to-day operations, with a focus on global product and business development strategies.

The company elaborated on Tulip’s qualifications:

“Tulip has spent more than 25 years in the development and commercialization of radiopharmaceuticals and imaging agents, with a track record of success in R&D, business development, brand and alliance management, and international business.

“From 2011-2015, he served in senior leadership roles at Navidea BioPharmaceuticals, Inc., where he led one of the few successful recent launches of an innovative radiopharmaceutical; established a number of global partnerships; and, in-licensed a pair of best-in-class neuroimaging assets.

“Previously, Tulip held senior leadership positions at Alseres Pharmaceuticals, Lantheus Medical Imaging (LMI), Bristol Myers Squibb (BMS), and DuPont, where his roles spanned product discovery and development, business and technology planning, brand and alliance management and international business management. While at BMS and DuPont, he was instrumental in the development, commercialization and international management of the highly successful nuclear cardiology franchise; successfully built the BMS Medical Imaging international business; and led planning activities for innovative PET tracers at LMI/BMS.

“He was a board member of the Academy of Molecular Imaging and Chairperson of its Institute for Molecular Technologies. Tulip was chairperson of the Society of Nuclear Medicine Corporate Advisory Board and served as a director of the Council on Radionuclides and Radiopharmaceuticals. He serves on the board of directors of the Medical Imaging Technology Association (MITA) and leads its PET Working Group.

“He earned a B.S. from the University of Vermont, and an M.S. and Ph.D. from the Northwestern University.”

In addition, Walter Witoshkin will take on the role of interim chairman of the board. Witoshkin has been a member of the board since 2011, the release stated.

FluoroPharma Medical’s previous chairman and CEO, Thijs Spoor, will remain a member of the board, according to the company.

FluoroPharma Medical also announced the resignation of board member Joseph A. Pierro, as well as the appointment of new board member Austin Lewis IV, CEO of Lewis Asset Management Corporation.

Send Montclair news tips and press releases to eric.kiefer@patch.com